Walder Wyss advised RhyGaze AG on the deal. RhyGaze, a biotechnology company based in Basel and Philadelphia has secured a Series A financing of USD 86...
RhyGaze AG’s $86 Million Series A Financing Round
SixPeaks Bio AG’s $110 Million Series A Financing Round
Walder Wyss advised SixPeaks Bio AG while Lenz & Staehelin acted as Swiss counsel to AstraZeneca. SixPeaks Bio AG has secured USD30 million in Series A...
Axalta Coating Systems Group’s Acquisition of Andre Koch AG
Walder Wyss advised Axalta Coating Systems on this transaction. Axalta Coating Systems Group (NYSE: AXTA) acquired André Koch AG, an established provider of car repair and...
Boehringer Ingelheim’s CHF450 Million Acquisition of T3 Pharmaceuticals AG
Walder Wyss advised Boehringer Ingelheim in the transaction. Boehringer Ingelheim announced the acquisition of privately-held T3 Pharmaceuticals AG, a clinical stage Swiss biotech company, for an...
Nouscom’s €67.5 Million Oversuscribed Series C Financing Round
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
CONVOTIS GmbH’s Acquisition of Acdalis AG
Walder Wyss advised CONVOTIS on all aspects of Swiss law on the transaction. CONVOTIS strengthens its position in Switzerland with the acquisition of acdalis AG, a...
Pierre Fabre Laboratories’ Acquisition of Vertical Bio AG
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
Alentis Therapeutics’ $105 Million Series C Funding Round
Walder Wyss advises Alentis Therapeutics on the financing. Alentis Therapeutics has announced $105 million in Series C financing. The funding round was led by Jeito Capital...
BC Platforms’ USD 20 Million Growth Financing
Walder Wyss advised BC Platforms on the deal. BC Platforms announced a USD 20m growth financing led by Jolt Capital. BC Platforms is a global leader in...
Vector BioPharma’s USD 30 Million Series A Funding Round
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
BioVersys’ CHF 24.2 Million Series C Financing Round
MLLStart! advised Clinical Research Ventures. Walder Wyss advises BioVersys. BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for...
Engimmune Therapeutics’ CHF 15.5 Million Seed Financing Round
Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings. Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led...